Ecopetrol
EC
Petroleo Brasileiro SA Petrobras
PBR
Meta Platforms
META
Vale SA
VALE
Alphabet-A
GOOGL
US Stock MarketDetailed Quotes
PRTC Puretech Health
- 17.900
- +0.350+1.99%
Trading Jan 10 09:30 ET
428.56MMarket Cap-5.97P/E (TTM)
17.900High17.900Low394Volume17.900Open17.550Pre Close7.05KTurnover0.00%Turnover RatioLossP/E (Static)23.94MShares34.00052wk High1.36P/B283.95MFloat Cap17.04052wk Low--Dividend TTM15.86MShs Float65.900Historical High--Div YieldTTM0.00%Amplitude17.040Historical Low17.900Avg Price1Lot Size
Puretech Health Stock Forum
Sign in to post a comment
NOTE!
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NE...
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NE...
100
30
15
$Puretech Health (PRTC.US)$
The FDA Has Granted Fast Track Designation To PureTech Health's LYT-200 For Acute Myeloid Leukemia
Benzinga· 04:081min
Puretech Health(PRTC.US)
Single agent and combination data from Phase 1b AML/MDS trial presented at ASH 2024 showed potential of LYT-200 to serve broad range of patients across various lines of treatmentLYT-200 is currently being evaluated in two Phase 1/2 trials for the potential treatment of AML/MDS and head and neck cancers
The FDA Has Granted Fast Track Designation To PureTech Health's LYT-200 For Acute Myeloid Leukemia
Benzinga· 04:081min
Puretech Health(PRTC.US)
Single agent and combination data from Phase 1b AML/MDS trial presented at ASH 2024 showed potential of LYT-200 to serve broad range of patients across various lines of treatmentLYT-200 is currently being evaluated in two Phase 1/2 trials for the potential treatment of AML/MDS and head and neck cancers
No comment yet
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
151158967 : Thank you, @Jaguar8 . Your hard work is appreciated!
103687630 : I think, what do you think of ONDS? There was good news on Wednesday but it went down. Do you think there is a chance for a rebound?
Jaguar8 OP 103687630 : I didn’t choose it because it didn’t specify how much is the contract.
103687630 Jaguar8 OP : Okay, thank you for your reply
70761249 : Can VERI make a breakthrough in the short term? The recent wildfires in Southern California are really heartbreaking, causing significant disappointment in the credibility of the media and government.
View more comments...